Melanocortin receptor agonist studied for sexual function (erectile and arousal pathways), skin pigmentation, and appetite suppression via CNS mechanisms.
Melanotan II (MT-2) is a synthetic analog of alpha-MSH that simultaneously activates several melanocortin receptors — the ones involved in skin pigmentation, sexual function, appetite, and energy metabolism. It was originally developed in the 1980s and 1990s as a potential tanning compound and later studied for sexual dysfunction. Researchers eventually moved on from it: its broad, non-selective receptor activity made it difficult to develop into a safe pharmaceutical. A refined successor — bremelanotide (PT-141), which focuses on the sexual function pathway without the strong tanning effect — became FDA-approved. MT-2 itself was never approved and carries a less favorable profile than its successor.
Sexual Function Research
MT-2's most studied application was erectile dysfunction and sexual arousal. Research in men showed it could produce erections and increase sexual desire through MC4R activation in brain regions involved in motivation and desire. This was the finding that ultimately led to the development of bremelanotide — a modified, more selective compound that retained the sexual function effects while reducing the tanning and cardiovascular side effects. The sexual function research on MT-2 is essentially the origin story of an approved drug.
Melanin and Tanning Research
MT-2 stimulates melanin production strongly through MC1R activation in skin cells, producing noticeable skin darkening. Early research interest was in whether it could serve as a sunless tanning agent or provide photoprotection for people with photosensitivity conditions. That application was not pursued once the side effect profile became clearer. Melanotan I (afamelanotide), a different compound, was later developed specifically for photoprotection and received approval for a rare photosensitivity disorder.
Appetite and Metabolic Research
MC4R activation reduces appetite, and MT-2 activates MC4R as part of its broad receptor profile. This contributed to appetite suppression observed in research subjects. The MC4R pathway is an active area of metabolic research, though more selective compounds have since been developed to explore it without the broader receptor activity that made MT-2 impractical.
Stimulates erections and sexual arousal through central melanocortin receptor activation — the finding that led to bremelanotide.
Strongly induces melanin production and skin darkening through MC1R activation.
Reduces appetite through MC4R activation.
Development was discontinued due to an unfavorable side effect profile; more selective successor compounds were developed instead.
MT-2 is not FDA-approved. Development was set aside in favor of more selective compounds — bremelanotide for sexual function and afamelanotide for photoprotection — that achieved better outcomes with fewer off-target effects. The broad receptor activation that makes MT-2 wide-ranging in its effects also makes it difficult to use predictably. Nausea is common. In men, unwanted erections are a frequent side effect. Skin darkening is significant and persistent. Changes to existing moles and development of new pigmented lesions have been observed and should be monitored. Blood pressure increases after dosing.
The melanocortin system is a family of receptors found in the skin, brain, and metabolic tissues that respond to alpha-MSH and related hormones. Each receptor has a distinct role: MC1R drives melanin production in skin cells, MC4R influences appetite and sexual arousal circuits in the brain, MC3R affects energy metabolism. MT-2 activates all of these simultaneously rather than targeting any one selectively. That broad activation is what made it interesting as a research tool — it showed researchers which effects came from which receptor — but it is also what made it impractical as a therapeutic. A drug that stimulates pigmentation, erections, and appetite suppression all at once, with cardiovascular effects on top, is very difficult to dose and manage. The lesson from MT-2 research was that selectivity matters, and the better compounds that came after it were built with that lesson in mind.
MT-2 is not FDA-approved. The side effects documented in research include nausea, blood pressure increases, and in men, unwanted erections — these are extensions of its pharmacological effects rather than unexpected toxicity. Skin darkening is marked and persistent. Changes to moles and pigmented lesions have been observed and should be monitored in anyone who uses it. The blood pressure effect is transient but meaningful for people with cardiovascular considerations. The more clinically advanced successor compounds — bremelanotide and afamelanotide — address specific applications with better characterized safety profiles and, in both cases, regulatory approval.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
0.25–1mg in research literature; titration from low doses noted in studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Melanotan-II: Effects on Erectile Function in Men with Psychogenic Erectile Dysfunction
Journal of Urology • 2000
• DOI: 10.1016/S0022-5347(05)67473-3
Appetite Suppression and Altered Food Preferences Coincide with Changes in Appetite-Mediating Hormones During Energy Deficit at High Altitude, But Are Not Affected by Protein Intake
Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.